Sunitinib is a multi-targeted receptor tyrosine kinase (e.g. PDGFR) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma and gastrointestinal stroma tumors. Here, PDGFRB is linked to gastrointestinal stromal tumor.